Cartesian Therapeutics, Inc.

NASDAQ:RNAC

Biotechnology

Healthcare
$6.12 -4.15%

-$0.41 today

Market cap
$186.68M
Beta
0.78
P/E (TTM)
-1.7
EPS (TTM)
-$5.65
52W Low $5.60High $15.57

Volume 0.23M

Average 0.26M

Income Statement

Follow revenue through to earnings.

Revenue

$2.80M

FY 2025 · Annual

-92.8% YoY

Operating Income

-$86.70M

FY 2025 · Annual

Net Income

-$130.30M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue85.08M110.78M26M38.91M2.8M
Cost of Revenue02.04M000
Gross Profit85.08M108.74M26M38.91M2.8M
Gross Margin100.0%98.2%100.0%100.0%100.0%
Research & Development68.74M72.38M71.26M45.11M58.03M
Selling, General & Admin20.94M23.86M40.45M30.13M31.47M
Operating Expenses89.67M94.2M112.42M82.81M89.5M
Depreciation & Amortization1.72M2.04M843K1.15M2.96M
EBITDA(5.16M)39.84M(235.03M)(75.99M)(136.54M)
EBITDA Margin-6.1%36.0%-903.8%-195.3%-4881.5%
Operating Income(4.6M)14.54M(86.42M)(43.9M)(86.71M)
Operating Margin-5.4%13.1%-332.3%-112.8%-3099.9%
Interest Income004.96M7.39M6.58M
Interest Expense2.84M3.03M2.83M00
Other Income / Expenses(5.12M)20.23M(152.29M)(33.24M)(52.79M)
Income Before Tax(9.72M)34.77M(238.71M)(77.14M)(139.5M)
Pre-Tax Margin-11.4%31.4%-918.0%-198.2%-4987.3%
Income Tax Expense15.97M(609K)(19M)287K(9.19M)
Net Income(25.69M)35.38M(219.71M)(77.42M)(130.3M)
Net Margin-30.2%31.9%-844.9%-199.0%-4658.6%
EPS (Basic)(6.74)7.33(49.76)(2.99)(5.02)
EPS (Diluted)(6.60)3.00(49.76)(3.29)(5.02)
Weighted Avg Shares3.18M4.02M5.17M25.91M25.97M
Weighted Avg Shares (Diluted)3.18M4.05M5.17M23.69M25.97M

RNAC Earnings Waterfall · TTM

NASDAQ:RNAC · Revenue to Net Income

Key Ratios

EPS$-5.70
Gross Margin-607.8%
Net Margin-15655.3%
P/E Ratio0.2
P/S Ratio952.2

Analysis

$1.8M of revenue converted into -$151.8M of net income for the selected period. Gross margin is -607.8% and net margin is -15655.3%, showing how much revenue survives after costs and taxes. EPS is $-5.70, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 6, 2026
8-KCurrent reportNov 5, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportSep 29, 2026
SC 13GSC 13G filingAug 13, 2026

How much revenue does RNAC generate?

Cartesian Therapeutics, Inc. (RNAC) reported $2.80M of revenue in fiscal 2025.

Is RNAC profitable?

Cartesian Therapeutics, Inc. (RNAC) reported -$130.30M of net income, with a net margin of -4658.6%.